Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer

Dysregulational EGFR, KRAS, and mTOR pathways cause metabolic reprogramming, leading to progression of gastric cancer. Afatinib (Afa) is a broad-spectrum tyrosine kinase inhibitor that reduces cancer growth by blocking the EGFR family. MicroRNA 125 (miR-125) reportedly diminishes EGFRs, glycolysis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Yu-Li, Wang, Tse-Yuan, Chen, Chun-Jung, Chang, Yih-Hsin, Lin, Anya Maan-Yuh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504622/
https://www.ncbi.nlm.nih.gov/pubmed/36145507
http://dx.doi.org/10.3390/pharmaceutics14091759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504622/
https://www.ncbi.nlm.nih.gov/pubmed/36145507
http://dx.doi.org/10.3390/pharmaceutics14091759

Ejemplares similares